Advertisement

European Journal of Clinical Pharmacology

, Volume 22, Issue 1, pp 71–75 | Cite as

Pharmacokinetics of ceftriaxone following intravenous administration of a 3 g dose

  • P. J. McNamara
  • K. Stoeckel
  • W. H. Ziegler
Originals

Summary

The pharmacokinetic parameters of total (bound and unbound) and free (unbound) ceftriaxone in six healthy volunteers after intravenous injection of 39 were compared with low-dose data from a previous study. The dose-dependent behaviour of total drug was considerably more pronounced after the 3 gram dose. In contrast, total body clearance (Cl S F =258 ml/min), renal clearance (Cl R F =170 ml/min) and volume of distribution (V D(β) F =168 l) of free (unbound) drug did not differ from the data reported earlier. There was no significant change in biological half-life (t1/2(β)=7.8 h) or in the fraction excreted unchanged in urine (fu=0.67).

Key words

cephalosporin ceftriaxone protein binding non-linear pharmacokinetics intravenous injection plasma levels 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Allaz A-F, Dayer P, Fabre J, Rudhardt M, Balant L (1979) Pharmacocinétique d'une nouvelle céphalosporine, la céfopérazone. Schweiz Med Wochenschr 109: 1999–2005PubMedGoogle Scholar
  2. 2.
    Angehrn P, Probst PJ, Reiner R, Then RL (1980) Ro 13-9904, a long-acting broad-spectrum cephalosporin: in vitro and in vivo studies. Antimicrob Agents Chemother 18: 913–921PubMedGoogle Scholar
  3. 3.
    Craig WA (1980) Single dose pharmacokinetics of cefoperazone following intravenous administration. Clin Ther 3: 46–49PubMedGoogle Scholar
  4. 4.
    Helwig JT, Council KA (eds) (1979) SAS user's guide. SAS Institute Inc., RaleighGoogle Scholar
  5. 5.
    Kurihara J, Matsumoto K, Uzuka Y, Shishido H, Nagatake T, Yamada H, Yoshida T, Oguma T, Kimura Y, Tochino Y (1980) Human pharmacokinetics of 6059 S. In: Nelson JD, Grassi C (eds) Current chemotherapy and infectious disease. American Society for Microbiology, Washington, DC, pp 110–111Google Scholar
  6. 6.
    Lode H, Kemmerich B, Koeppe P, Belmega D, Jendroschek H (1980) Comparative pharmacokinetics of cefoperazone and cefotaxime. Clin Ther 3: 80–88PubMedGoogle Scholar
  7. 7.
    Lüthy R, Münch R, Blaser J, Bhend W, Siegenthaler W (1979) Human pharmacology of cefotaxime (HR 756), a new cephalosporin. Antimicrob Agents Chemother 16: 127–133PubMedGoogle Scholar
  8. 8.
    Nightingale CM, Green DS, Quintiliani R (1975) Pharmacokinetics and clinical use of cephalosporin antibiotics. J Pharm Sci 64: 1899–1927PubMedGoogle Scholar
  9. 9.
    Reiner R, Weiss U, Brombacher U, Lanz P, Montavon M, Furlenmeier A, Angehrn P, Probst PJ (1980) Ro 13-9904/001, a novel potent and long-acting parenteral cephalosporin. J Antibiot 33: 783–786PubMedGoogle Scholar
  10. 10.
    Scatchard G (1949) The attraction of protein for small molecules and ions. Ann NY Acad Sci 51: 660–672Google Scholar
  11. 11.
    Snedecor GW, Cochran WG (1967) Statistical methods, 6th edn. The Iowa State University Press, AmesGoogle Scholar
  12. 12.
    Stoeckel K, McNamara PJ, Brandt R, Plozza-Nottebrock H, Ziegler WH (1981) The effects of concentration-dependent plasma protein binding on the pharmacokinetics of ceftriax-one, a new parenteral cephalosporin. Clin Pharmacol Ther 29: 650–657PubMedCrossRefGoogle Scholar
  13. 13.
    Trautmann KH, Haefelfinger P (1981) Determination of Ro 13-9904 in plasma, urine and bile by means of ion-pair reversed phase chromatography. J High Resol Chromatogr 4: 54–59CrossRefGoogle Scholar
  14. 14.
    Wise R, Baker S, Livingston R (1980) Comparison of cefotaxime and moxalactam pharmacokinetics and tissue levels. Antimicrob Agents Chemother 18: 369–371PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1982

Authors and Affiliations

  • P. J. McNamara
    • 1
  • K. Stoeckel
    • 1
  • W. H. Ziegler
    • 1
  1. 1.Biological Pharmaceutical Research DepartmentF. Hoffmann-La Roche & Co. Ltd.BaselSwitzerland

Personalised recommendations